Welcome to our dedicated page for Talis Biomedical news (Ticker: TLIS), a resource for investors and traders seeking the latest updates and insights on Talis Biomedical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talis Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talis Biomedical's position in the market.
Talis Biomedical Corporation (Nasdaq: TLIS) has withdrawn its FDA Emergency Use Authorization application for the Talis One COVID-19 test in CLIA moderate settings. The decision comes after the FDA raised concerns about the sensitivity of the comparator assay used in the primary study. Talis will now focus on a new EUA application for CLIA waived settings, planning to initiate a clinical validation study using a different comparator assay. The company aims to submit the new EUA early in Q2 2021, prioritizing high-quality testing solutions for healthcare providers.
Talis Biomedical Corporation (Nasdaq: TLIS) announced the completion of its initial public offering (IPO) of 15,870,000 shares at $16.00 per share, raising approximately $253.9 million in gross proceeds. The offering included 2,070,000 shares sold due to underwriters' full exercise of their option. The IPO shares commenced trading on February 12, 2021. J.P. Morgan, BofA Securities, and Piper Sandler served as book-running managers. Talis is focused on developing innovative molecular diagnostic tests for infectious diseases, beginning with COVID-19.
Talis Biomedical Corporation (Nasdaq: TLIS) has priced its initial public offering (IPO) at $16.00 per share, aiming to raise approximately $220.8 million before expenses. The offering consists of 13,800,000 shares, with an option for underwriters to purchase an additional 2,070,000 shares. Talis is set to begin trading on the Nasdaq Global Market on February 12, 2021, with the IPO closing on February 17, 2021. J.P. Morgan, BofA Securities, and Piper Sandler & Co. are leading this offering.